Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 3
1970 5
1971 2
1973 3
1974 5
1975 3
1976 2
1977 5
1978 5
1979 1
1980 2
1981 6
1982 4
1983 1
1984 5
1985 4
1986 8
1987 10
1988 8
1989 19
1990 16
1991 13
1992 11
1993 19
1994 20
1995 21
1996 17
1997 23
1998 26
1999 20
2000 18
2001 19
2002 12
2003 18
2004 25
2005 25
2006 27
2007 35
2008 20
2009 13
2010 26
2011 21
2012 26
2013 38
2014 28
2015 24
2016 23
2017 28
2018 21
2019 25
2020 22
2021 28
2022 25
2023 15
2024 17
2025 20
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

830 results

Results by year

Filters applied: . Clear all
Page 1
Rifaximin treatment in hepatic encephalopathy.
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Bass NM, et al. N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893. N Engl J Med. 2010. PMID: 20335583 Free article. Clinical Trial.
More than 90% of patients received concomitant lactulose therapy. The incidence of adverse events reported during the study was similar in the two groups, as was the incidence of serious adverse events. ...
More than 90% of patients received concomitant lactulose therapy. The incidence of adverse events reported during the study was simil …
Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Sanyal AJ, Kowdley KV, Reau NS, Pyrsopoulos NT, Allen C, Heimanson Z, Bajaj JS. Sanyal AJ, et al. Hepatol Commun. 2024 May 10;8(6):e0436. doi: 10.1097/HC9.0000000000000436. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727685 Free PMC article. Clinical Trial.
METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted. RESULTS AND CONCLUSION: Rifaximin plu …
METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone …
Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: A randomized crossover trial.
Algera JP, Demir D, Törnblom H, Nybacka S, Simrén M, Störsrud S. Algera JP, et al. Clin Nutr. 2022 Dec;41(12):2792-2800. doi: 10.1016/j.clnu.2022.11.001. Epub 2022 Nov 4. Clin Nutr. 2022. PMID: 36384081 Free article. Clinical Trial.
At baseline, severity of GI symptoms and gut microbial fermentation were assessed (every 15 min, 4 h) during the Lactulose Nutrient Challenge Test (LNCT). Clinical response and FODMAP sensitivity were defined by reduction after low FODMAP period, and increase after moderat …
At baseline, severity of GI symptoms and gut microbial fermentation were assessed (every 15 min, 4 h) during the Lactulose Nutrient C …
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.
Bajaj JS, Fagan A, Gavis EA, Sterling RK, Gallagher ML, Lee H, Matherly SC, Siddiqui MS, Bartels A, Mousel T, Davis BC, Puri P, Fuchs M, Moutsoglou DM, Thacker LR, Sikaroodi M, Gillevet PM, Khoruts A. Bajaj JS, et al. J Hepatol. 2025 Jul;83(1):81-91. doi: 10.1016/j.jhep.2024.12.047. Epub 2025 Jan 10. J Hepatol. 2025. PMID: 39800192 Clinical Trial.
METHODS: We performed a phase II randomized, placebo-controlled, double-blind, clinical trial of capsule and enema FMT in patients with cirrhosis and HE on lactulose and rifaximin. Participants were randomized into four groups (3 active doses; 2 active and 1 placebo dose; …
METHODS: We performed a phase II randomized, placebo-controlled, double-blind, clinical trial of capsule and enema FMT in patients with cirr …
Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Rahimi RS, et al. JAMA Intern Med. 2014 Nov;174(11):1727-33. doi: 10.1001/jamainternmed.2014.4746. JAMA Intern Med. 2014. PMID: 25243839 Free PMC article. Clinical Trial.
OBJECTIVE: To compare polyethylene glycol 3350-electrolyte solution (PEG) and lactulose treatments in patients with cirrhosis admitted to the hospital for HE. We hypothesized that rapid catharsis of the gut using PEG may resolve HE more effectively than lactulose. D …
OBJECTIVE: To compare polyethylene glycol 3350-electrolyte solution (PEG) and lactulose treatments in patients with cirrhosis admitte …
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A. Jain A, et al. Hepatology. 2022 May;75(5):1194-1203. doi: 10.1002/hep.32255. Epub 2021 Dec 21. Hepatology. 2022. PMID: 34822189 Clinical Trial.
APPROACH AND RESULTS: In a double-blind randomized placebo-controlled trial, 140 patients were randomized to a combination of LOLA, lactulose, and rifaximin (n = 70) or placebo, lactulose, and rifaximin (n = 70). LOLA was given as continuous intravenous infusion at …
APPROACH AND RESULTS: In a double-blind randomized placebo-controlled trial, 140 patients were randomized to a combination of LOLA, lactu …
A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. Sharma BC, et al. Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23. Am J Gastroenterol. 2013. PMID: 23877348 Clinical Trial.
Drugs used in the treatment of HE are primarily directed at the reduction of the blood ammonia levels. Rifaximin and lactulose have shown to be effective in HE. We evaluated the efficacy and safety of rifaximin plus lactulose vs. lactulose alone for treatment …
Drugs used in the treatment of HE are primarily directed at the reduction of the blood ammonia levels. Rifaximin and lactulose have s …
Effect, Tolerability, and Safety of Exclusive Palatable Elemental Diet in Patients With Intestinal Microbial Overgrowth.
Rezaie A, Chang BW, de Freitas Germano J, Leite G, Mathur R, Houser K, Hosseini A, Brimberry D, Rashid M, Mehravar S, Villanueva-Millan MJ, Sanchez M, Weitsman S, Fajardo CM, Rivera IG, Joo L, Chan Y, Barlow GM, Pimentel M. Rezaie A, et al. Clin Gastroenterol Hepatol. 2025 Nov;23(12):2306-2317.e7. doi: 10.1016/j.cgh.2025.03.002. Epub 2025 Apr 4. Clin Gastroenterol Hepatol. 2025. PMID: 40189034 Free article. Clinical Trial.
METHODS: Adult subjects with positive lactulose breath tests for SIBO and/or IMO completed 1 week of screening, 2 weeks of exclusive oral PED, and 2 weeks of follow-up during reintroduction of regular diet. ...Secondary end points included tolerability, rate of normalizati …
METHODS: Adult subjects with positive lactulose breath tests for SIBO and/or IMO completed 1 week of screening, 2 weeks of exclusive …
Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
Jhajharia A, Singh S, Jana S, Ashdhir P, Nijhawan S. Jhajharia A, et al. Sci Rep. 2024 May 24;14(1):11862. doi: 10.1038/s41598-024-62293-8. Sci Rep. 2024. PMID: 38789596 Free PMC article. Clinical Trial.
Hepatic encephalopathy (HE), a morbid ordeal affecting chronic liver disease patients always insists for the search of a rational, superior & infallible agent beyond the time-proven standards i.e., Lactulose & Rifaximin. In this RCT, we compared the efficacy of int …
Hepatic encephalopathy (HE), a morbid ordeal affecting chronic liver disease patients always insists for the search of a rational, superior …
Fructose transport mechanisms in humans.
Shi X, Schedl HP, Summers RM, Lambert GP, Chang RT, Xia T, Gisolfi CV. Shi X, et al. Gastroenterology. 1997 Oct;113(4):1171-9. doi: 10.1053/gast.1997.v113.pm9322512. Gastroenterology. 1997. PMID: 9322512 Clinical Trial.

A sucrose solution produced greater (P < 0.05) sucrose absorption than a sucrose-acarbose solution. Lactulose absorption (0.016-0.039 mmol.h-1.cm-1) was observed from solutions containing glucose or sucrose. ...These data suggest that free fructose and glucose transport

…

A sucrose solution produced greater (P < 0.05) sucrose absorption than a sucrose-acarbose solution. Lactulose absorption (0.016-0.

…
830 results